-
摘要: 目的:探讨重组人白介素-11治疗急性髓系白血病(AML)化疗后血小板减少的有效性和安全性。方法:分别选择21例患者43例次化疗为治疗组和对照组,治疗组化疗结束24 h或血小板低于100×109/L时给予皮下注射重组人白介素-11 25 μg·kg-1·d-1,观察患者化疗后血小板计数变化、输注血小板剂量和药物不良反应。结果:治疗组和对照组化疗后最低血小板计数和输注血小板次数差异无统计学意义(P>0.05)。血小板恢复至50×109/L的天数和恢复至100×109/L的天数差异有统计学意义(P<0.01),治疗组较对照组平均约提前2.5 d。治疗组耐受性良好,观察到的不良反应有全身乏力、水肿、注射部位疼痛,其发生率均不到10%。结论:重组人白介素-11辅助治疗AML可以一定程度上缩短患者化疗后血小板低下持续的时间,且耐受性良好。
-
-
[1] LEONARD J P,QUINTO C M,KOZITZA M K,et al.Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin[J].Blood,1994,83:1499-1506.
[2] TEPLER I,ELIAS L,SMITH J W,et al.A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy[J].Blood,1996,87:3607-3614.
[3] BHATIA M,DAVENPORT V,CAIRO M S.The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors,lymphoma,acute myeloid leukemia and bone marrow failure syndromes[J].Leuk Lymphoma,2007,48:9-15.
[4] 张秋荣,吴德沛,陈令松.重组人白细胞介素-11在初诊急性白血病患者中的临床应用[J].临床血液学杂志,2004,17(5):263-265.
[5] 王开泰,陆红娟.重组人白介素-11对血液肿瘤化疗后血小板减少恢复的效果[J].临床血液学杂志,2007,20(6):332-334.
[6] CRIPE L D,RADER K,TALLMAN M S,et al.Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia(AML)receiving high-dose cytarabine during induction:ECOG 3997[J].Leuk Res,2006,30:823-827.
[7] 朱卫国,董晓燕,蒋志相,等.重组人白介素-11治疗46例急性白血病化疗后血小板减少[J].肿瘤学杂志,2009,15(2):170-171.
[8] ELLIS M,ZWAAN F,HEDSTROM U,et al.Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy:a double-blind placebo-controlled randomised trial[J].Lancet,2003,361:275-280.[JY,2][HT5"K](收稿日期:2011-12-27修回日期:2012-03-11)
-
计量
- 文章访问数: 400
- PDF下载数: 199
- 施引文献: 0
下载: